Sheldon Harigel, MD
Family Medicine · Lawrenceburg, TNNPI 1407090731
Payments from drug & device makers
Across 160 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$607
- Novo Nordisk$351
- Johnson & Johnson$196
- Novartis$156
- Lilly USA, LLC$117
- Medtronic$115
- plus $877 from 23 others
What the payments were for
- Food & beverage$2,419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $607 |
| Novo Nordisk | 29 | $351 |
| Johnson & Johnson | 13 | $196 |
| Novartis | 8 | $156 |
| Lilly USA, LLC | 9 | $117 |
| Medtronic | 2 | $115 |
| Pfizer | 8 | $111 |
| AstraZeneca | 6 | $92 |
| Abbott | 3 | $77 |
| Exact Sciences | 4 | $74 |
| Merck | 4 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $42 |
| Bayer | 2 | $37 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $35 |
| Mylan Specialty L.p. | 2 | $34 |
| Philips North America LLC | 2 | $31 |
| Shire North American Group Inc | 2 | $30 |
| GSK | 2 | $28 |
| Boehringer Ingelheim | 2 | $26 |
| Orexo US, Inc. | 2 | $26 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$127
How this compares
$2,419 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $150,894 |
| MounjaroTirzepatide | 103 | $125,604 |
| EliquisApixaban | 137 | $112,212 |
| Tresiba Flextouch U-200Insulin Degludec | 91 | $94,576 |
| MyrbetriqMirabegron | 57 | $44,182 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $34,319 |
| LinzessLinaclotide | 31 | $32,954 |
| FarxigaDapagliflozin Propanediol | 25 | $30,719 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $29,948 |
| EntrestoSacubitril/Valsartan | 17 | $26,488 |
| TrulicityDulaglutide | 24 | $24,229 |
| JardianceEmpagliflozin | 19 | $22,997 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $21,761 |
| XareltoRivaroxaban | 18 | $19,156 |
| SantylCollagenase Clostridium Hist. | 17 | $18,023 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $351 | $150,894145 claims |
| Lilly USA, LLCMounjaro, Trulicity | $117 | $149,833127 claims |
| PfizerEliquis | $111 | $112,212137 claims |
| GSKTrelegy Ellipta | $28 | $34,31940 claims |
| AbbVieLinzess | $607 | $32,95431 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $26 | $31,04034 claims |
| AstraZenecaFarxiga | $92 | $30,71925 claims |
| NovartisEntresto | $156 | $26,48817 claims |
| Johnson & JohnsonXarelto | $196 | $19,15618 claims |
| MerckJanuvia | $46 | $17,92911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Lawrenceburg
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.